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Manifestations of human monocytic ehrlichiosis
(HME), a tick-borne infection caused by Ehrlichia chaffeen-
sis, range from asymptomatic disease to fulminant infection
and may be particularly severe in persons infected with
HIV. We conducted a serologic study to determine the epi-
demiology of HME in HIV-positive patients residing in an
HME-endemic area. We reviewed charts from a cohort of
133 HIV-positive patients who were seen during the 1999
tick season with symptoms compatible with HME (n=36) or
who were asymptomatic (n=97). When available, paired
plasma samples obtained before and after the tick season
were tested by using an indirect immunofluorescence
assay (IFA) to detect antibodies reactive to E. chaffeensis.
Two symptomatic incident cases were identified by IFA,
resulting in a seroincidence of 6.67% among symptomatic
HIV-positive participants with paired samples available for
testing and 1.64% overall. The baseline seroprevalence of
HME was 0%. In contrast to infection in immunocompetent
patients,  E. chaffeensis infection in HIV-positive persons
typically causes symptomatic disease.
D
uring the last 25 years, the discovery of a number of
newly identified infectious agents, such as Borrelia
burgdorferi, Legionella pneumophila, and HIV, has raised
concern in both the medical and lay communities about
novel infectious threats to human populations. Among
these emerging pathogens are several species of Ehrlichia,
small, gram-negative bacteria transmitted by arthropod
vectors that can cause human disease, such as human
monocytic ehrlichiosis (HME). First described in 1986 (1),
HME is caused by Ehrlichia chaffeensis, an organism
transmitted primarily by the lone star tick (Amblyomma
americanum) (2). Infection with E. chaffeensis can range
from being clinically asymptomatic to causing a severe life-
threatening illness. HME typically causes systemic symp-
toms (including fever, headache, malaise, rash, abdominal
pain, nausea, and cough) and laboratory signs (leukopenia,
thrombocytopenia, and elevated transaminase levels).
Rarely, patients have fulminant infection with disseminated
intravascular coagulation, sepsis, and adult respiratory dis-
tress syndrome, leading to death (2). Asymptomatic infec-
tion with E. chaffeensis may occur frequently, as suggested
in a recent seroepidemiologic study in which 67% of mili-
tary recruits in an E. chaffeensis–endemic area seroconvert-
ed without symptoms (3). 
The risk for HME in immunocompromised patients is
unknown; however, numerous case reports and reviews
have described severe ehrlichial infection in immunosup-
pressed patients (4–6), including several reports of rapidly
fatal infection with E. chaffeensis in AIDS patients (7–9).
Diagnosis of HME in HIV-positive patients is often con-
founded by the fact that the signs and symptoms of
ehrlichial infection mimic typical findings commonly
associated with HIV infection, its complications, and the
medications commonly used in treating such patients.
Delayed consideration and diagnosis of ehrlichial infection
may result in additional illness if antibiotic therapy is not
instituted promptly.
Studies investigating the epidemiology of E. chaffeen-
sis infection have focused on healthy persons living in
regions endemic for E. chaffeensis or clinical findings
among hospitalized case-patients (3,10–12). A systematic
evaluation of the seroepidemiology of ehrlichial disease in
HIV-infected persons has not been performed. We there-
fore conducted a descriptive seroepidemiologic study to
ascertain the prevalence and incidence of E. chaffeensis
infections in HIV-infected persons located in an area
endemic for HME.
Methods
Selection of Patients
Participants were selected among HIV-positive patients
who receive their medical care at the Comprehensive Care
Center, an adult HIV-oriented primary care clinic located
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Georgia, USAin Nashville that serves middle Tennessee and surrounding
regions. Center records were retrospectively analyzed to
identify patients seen at the clinic for any reason between
March 1, 1999, and October 31, 1999 (the typical period of
tick activity in middle Tennessee). 
Symptomatic Patient Subset
Those patients discharged with diagnoses indicative of
potential ehrlichial infection, according to the International
Classification of Diseases, 9th Edition (ICD-9), were iden-
tified by means of a blinded database review. Specifically,
patients who were assigned the following ICD-9 codes
were selected for the study cohort: fever or fever of
unknown origin (780.6), viral infection (079.9), upper res-
piratory infection (465.9) or respiratory disease (478.9) not
otherwise specified, Lyme disease (088.81), rickettsial dis-
ease (specified, 083.8, or unspecified, 083.9), Rocky
Mountain spotted fever (082.0), tick bite (088.89), and
myalgias (729.1). To find potential participants who may
have been missed in the original search, a second database
search identified patients during the study period who were
prescribed doxycycline, the therapy of choice in the empir-
ic treatment of febrile illness during the tick season. 
Asymptomatic/Other Patient Subgroup
The rest of the study cohort comprised patients who
visited the center during the study period and who had
plasma banked for serologic investigation (see “Plasma
Collection”). To investigate the incidence of asymptomatic
Ehrlichia infection, patients were selected from a blinded
review of the center’s plasma sample log. Patients who had
banked plasma samples from the pretick season (between
September 15, 1998, and March 31, 1999) as well as from
the posttick season (after October 31, 1999) and who had
visited the center for routine follow-up during the study
period were selected for study. Records of patients identi-
fied as asymptomatic were reviewed for symptoms sug-
gestive of HME during the study period that were not
encoded with an ehrlichiosis-compatible ICD-9 diagnosis.
Chart Review
The center’s data charts were analyzed for demograph-
ic data (age at start of study period, race, sex, number of
clinic visits during the study period), past medical history,
medication history (the administration of highly active
antiretroviral therapy [HAART] and medication used as
prophylaxis against opportunistic infections), and HIV sta-
tus based on the most recent CD4 count and viral load
drawn before the study period began (March 1, 1999).
Charts from the symptomatic patients were further ana-
lyzed for symptoms suggestive of Ehrlichia infection,
including the presence or absence of fever, headache, rash,
fatigue, malaise, upper respiratory infection symptoms,
nausea, vomiting, myalgias, abdominal pain, and mental
status changes. Symptom history, laboratory parameters
(peripheral leukocyte count, platelet count, aspartate
aminotransferase, and alanine aminotransferase) at base-
line and during the acute illness, and illness outcomes
(including antibiotics prescribed, hospitalization, and
death) were also collected. Insufficient data on tick expo-
sure, tick bites, or outdoor activity were available to eval-
uate exposure risk factors for Ehrlichia infection.
Plasma Collection
Since 1998, the center has maintained a repository of
plasma samples frozen at –70°C by retaining specimens
obtained from patients during routine phlebotomy. All
patients who choose to participate in the plasma banking
provide written informed consent based on a protocol
approved by the Vanderbilt University Institutional
Review Board. The plasma log was cross-checked with the
study participant list identified from the database review as
outlined above. Participants with no banked plasma sam-
ple from before the onset of the study period (preseason
sample) or at the onset of clinical symptoms (acute sam-
ple) were excluded. Samples from at least 4 weeks after
the acute clinical illness or after the study period (postsea-
son sample) were also identified for most persons. Persons
with no further samples banked after their acute illness or
the study period were included only in determination of
seroprevalence. 
Serologic Testing
All preseason and postseason samples were tested in a
blinded fashion by indirect immunofluorescence assay for
antibody reactive with E. chaffeensis with an assay previ-
ously described for human granulocytic ehrlichiosis,
which has been widely employed for HME using different
antigen substrates (13). A reciprocal antibody titer of >64
was considered elevated and indicative of infection with E.
chaffeensis. Seroconversion to E. chaffeensis was defined
as a fourfold or greater increase in antibody titer between
acute-phase or preseason and convalescent-phase samples.
Statistical Analysis
Incidence rates were described as the number of cases
of seroconversion divided by the total population of inter-
est. We used 95% confidence intervals determined by
using Stata statistical software version 7.0 (Stata
Corporation, College Station, TX).
Results
We initially identified a total of 176 patients from the
center’s records; 43 were excluded because specimens for
testing were unavailable, leaving 133 in our study cohort.
Thirty-six (27.1%) had symptoms compatible with HME
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cline use, 7 found after chart review of initial asympto-
matic candidates), and 97 (72.9%) had no symptoms sug-
gestive of this diagnosis. Characteristics of the cohort are
shown in the Table. The median CD4 count was 370
cells/mm3. Symptomatic participants had significantly
more visits (p<0.001) to the clinic during the study period
and were significantly (p=0.035) more likely to have
received antibiotic therapy (excluding doxycycline; data
not shown). As doxycycline was used to select for sympto-
matic participants, doxycycline therapy was, not included
in the analysis of antibiotic use. Other characteristics
(specifically age, gender, baseline CD4 count, baseline
viral load, use of HAART, use of prophylaxis for oppor-
tunistic infection [Pneumocystis carinii pneumonia and
Mycobacterium avium complex], and average number of
visits during the study period) between the symptomatic
and asymptomatic subgroups did not differ significantly. 
None of the patient specimens obtained before the 1999
tick season had serologic evidence of prior Ehrlichia infec-
tion, resulting in a baseline seroprevalence of 0% for our
cohort. Of the 122 patients with paired samples available
(92 asymptomatic, 30 symptomatic), 1 patient had a clini-
cal syndrome compatible with HME and had a significant
rise in antibody titer to E. chaffeensis during the study
period (initial titer 64; postseason titer 1,024). Clinically
notable disease characterized by fever, myalgias/arthral-
gias, leukopenia, and thrombocytopenia developed in this
patient after tick exposure and required a 4-day hospital-
ization. During this hospitalization, his diagnosis was con-
firmed by conducting a polymerase chain reaction assay on
his serum, which was positive for E. chaffeensis. His
symptoms resolved after a course of doxycycline. A sec-
ond patient with a 10-day history of symptoms compatible
with HME (fatigue, cough, and overall malaise), but no
documentation of tick exposure or tick bite, had an initial
acute-phase titer of 512, drawn when first seen by a clini-
cian (10 days after symptom onset), fulfilling case criteria
for probable Ehrlichia infection (14). This patient did not
have an earlier preseason sample available for analysis but
did have a postseason titer of 512 obtained 4 months after
clinical illness, suggesting a prolonged elevation in anti-
body titer. He was thought to have an upper respiratory
tract infection by his primary caregiver, and doxycycline
was prescribed for his illness. His symptoms resolved
without hospitalization. 
These two cases resulted in a seroincidence among
symptomatic patients of 6.67% (95% confidence interval
[CI] 0.82, 22.1) and an overall incidence of 1.64% (95%
CI 0.2, 5.8). No asymptomatic cases were identified in our
cohort (upper 95% CI for seroconversion in the asympto-
matic population, 3.2%). 
Discussion
Researchers have conducted various serologic studies
to ascertain the epidemiology of E. chaffeensis infection in
specific populations. Carpenter et al. (10) found a seroin-
cidence of 25.7% in febrile patients in North Carolina with
a history of a recent tick bite. In a prospective seroepide-
miologic study of residents living in a rural community in
California, prevalence rates of 4.6% were reported, and
most of the infected participants recalled no recent com-
patible illness (11). In a comparison of two golf-oriented
retirement communities in middle Tennessee, one abutting
a wildlife-management area and one 20 miles away from
the area used as a control population, Standaert et al. found
seroprevalence rates of 12.5% and 3.3%, respectively (12).
A study on the seroprevalence in children residing in
HME-endemic areas, including Tennessee, found a sero-
prevalence rate (as defined by E. chaffeensis antibody titer
>1:80) of nearly 15% among children undergoing phle-
botomy in Nashville (15). None of these studies, however,
investigated the incidence rates for immunosuppressed
persons, such as persons infected with HIV, who may be at
increased risk for symptomatic disease after ehrlichial
infection.
Our findings indicate that the prevalence and incidence
of HME attributable to E. chaffeensis infection in an HIV-
positive population are quite low in a cohort of HIV-posi-
tive patients receiving care at an urban HIV clinic within
an HME-endemic region. The incidence rate in our study
was similar to those previously reported in a cohort of
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Table. Baseline characteristics of study cohort of HIV-positive 
persons residing in Tennessee
a 
Characteristic  N (% or range) 
Age (mean, y)  38.8 (21–75) 
Sex   
Male   107 (80.5%) 
Female  26 (19.5%) 
Baseline CD4 count (median, cells/mm
3)  370 (6–1,200) 
Baseline viral load (median, copies/dL)  1,003 (<400–>750,000) 
On prophylaxis   
HAART  122 (91.7%) 
OI prophylaxis  70 (52.6%) 
PCP prophylaxis
b  66 (49.6%) 
MAC prophylaxis
c  31 (23.3%) 
Average number of clinic visits
d  4.75 (1–13) 
Treated with antibiotic therapy
d,e  40/133 (30.1%) 
Treated with doxycycline
d  14/133 (10.5%) 
Hospitalized
d  7/133 (5.3%) 
aHAART, highly active antiretroviral therapy; OI, opportunistic 
infection; PCP, Pneumocystis carinii pneumonia; MAC, 
Mycobacterium avium complex.
 
bPCP prophylaxis: use of trimethoprim-sulfamethoxazole, dapsone, 
or aerosolized pentamidine therapy.  
cMAC prophylaxis: use of azithromycin or clarithromycin therapy.  
dDuring the study period. 
eAntibiotics used to treat the ongoing clinical symptoms; persons taking 
antibiotic therapy specifically for OI prophylaxis alone were not included. healthy military recruits in an area endemic for E. chaf-
feensis (1.3%) (3). However, only 33.3% of seropositive
persons in that study had a compatible febrile illness, and
none of these symptomatic seroconverters were sufficient-
ly ill to require medical care (3). In contrast, both of our
case-patients had symptomatic disease of sufficient sever-
ity to require medical care, and one required hospitaliza-
tion. Furthermore, none of our patients had serologic evi-
dence of asymptomatic infection during the study period.
Therefore, while the overall incidence of Ehrlichia infec-
tion was not increased in our cohort, these results are in
agreement with other studies that indicate that HME can
cause severe infection in HIV-positive persons.
Our patient with a diagnosis of probable HME had evi-
dence of a sustained antibody response. The acute-phase
serum sample and a convalescent-phase sample obtained 4
months later both had titers of 512. This finding suggests
that the immune response mounted by HIV-positive per-
sons against E. chaffeensis is durable and may persist for
several months, similar to the response seen in HIV-nega-
tive persons. Because of the low rate of seroconversion in
our cohort, we were unable to analyze data on specific risk
factors (e.g., CD4 count or use of HAART) that might pre-
dispose persons with HIV infection to ehrlichiosis. 
Our study has several limitations. The retrospective
design placed constraints on the data that could be
abstracted, thus introducing possible reporting bias. A
prospective study, in contrast, would allow investigators to
collect further information on exposure risks, such as level
of outdoor activity, and could reduce the variability in
symptom reporting found with our study. Our study popu-
lation could also lead to bias and, as a result, limit gener-
alizability of our results to the HIV-positive population as
a whole. The Comprehensive Care Center draws patients
from both metropolitan areas (Nashville) and rural com-
munities; however, our cohort may have been more metro-
politan and less likely to come into contact with wooded
environments. Also, HIV-infected patients who regularly
attended the clinic may have had more contact with the
healthcare delivery system and thus been more likely to
take regular antiretroviral medications that could reduce
their viral burden and concomitant immunodeficiency. As
a result, those patients who are noncompliant with follow-
up (and, by extension, antiviral therapy) may be at greater
risk for symptomatic infection and may have been missed
in our analysis. 
The use of serologic methods to determine actual
prevalence and incidence rates for the HIV-infected popu-
lation may also be problematic. A reduced antibody
response to various antigens, including those contained in
tetanus and pneumococcal vaccines, in HIV-infected
patients has been described in previous studies (16). A
potentially decreased ability to mount an immune response
to E. chaffeensis may have led to false-negative antibody
titers and an underestimate of the incidence of ehrlichiosis
in this population. Such a finding was highlighted in two
previous reports of HIV-positive persons with fatal E.
chaffeensis infection who did not mount an antibody
response during their illnesses (5,7). The serologic
response to ehrlichial infection may also be blunted or
inhibited by tetracycline therapy, which, when given early
in the course of Ehrlichia infections, inhibits the develop-
ment of a serologic response (10,12). Empiric treatment of
febrile patients with a clinical picture resembling ehrli-
chiosis in our population thus could have blunted the anti-
body response and led to a falsely low seroincidence and
prevalence. 
In conclusion, we found that levels of HME infection in
our HIV-positive cohort were similar to those in normal,
healthy persons who received intense exposure to the out-
doors in an HME-endemic area. However, both of our
case-patients had clinical infections, one requiring hospi-
talization. Caregivers of HIV-positive patients in regions
endemic for E. chaffeensis should consider ehrlichiosis as
part of the growing list of potential opportunistic infections
and maintain a high level of clinical suspicion for this dis-
ease. Prospective studies in HIV-positive populations are
needed to fully understand the extent of infection with E.
chaffeensis in these patients. 
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